Rituximab for treatment of intermediate and aggressive B-cell non-Hodgkin's lymphomas.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D054598:Blue Cross Blue Shield Insurance Plans; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D019458:Insurance Coverage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D013673:Technology Assessment, Biomedical; D014481:United States
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents